Solid Tumor Malignancies Clinical Trial
Official title:
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.
GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects. ;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04668833 -
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
|
Phase 2 | |
Recruiting |
NCT05085548 -
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT01924689 -
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
|
Phase 1 | |
Completed |
NCT01183364 -
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
|
Phase 1 | |
Terminated |
NCT00195156 -
Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
Terminated |
NCT01290380 -
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
Terminated |
NCT01118819 -
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
|
Phase 1 |